BEVACIZUMAB

Information current as at:

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Zirabev®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: Pfizer Australia Pty Ltd
Condition/indication: (therapeutic use): Advanced International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer; Advanced carcinoma of cervix; Relapsed or recurrent glioblastoma; Stage IV (metastatic) non-small cell lung cancer (NSCLC); Metastatic colorectal cancer.
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New listing (Minor)
Comment:: --
Other PBAC consideration:: --

Progress Details

Submission received for:: July 2020 PBAC meeting
Opportunity for consumer comment:: Has not yet commenced
PBAC meeting:: Held on 08/07/2020
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: Awaiting lodgement from pharmaceutical company
Lodgement of required documentation:: Not applicable
Agreement to listing arrangements:: Not applicable
Government processes:: Not applicable
Medicine listed on the PBS:: Not applicable

Glossary

PBAC Outcome

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

PBAC Public Summary Documents – July 2020

Case ID

a171

Page last updated

31 March 2026

Return to the Medicine Status Listing

v.9.19